Φορτώνει......
A new FGFR inhibitor disrupts the TGF‐β1‐induced fibrotic process
Pulmonary fibrosis (PF) is chronic and irreversible damage to the lung characterized by fibroblast activation and matrix deposition. Although recently approved novel anti‐fibrotic agents can improve the lung function and survival of patients with PF, the overall outcomes remain poor. In this study,...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Cell Mol Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6933341/ https://ncbi.nlm.nih.gov/pubmed/31692229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14793 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|